Page 2 - Daniel Mikol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting

NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaUnited statesShirley ryan abilitylabNancy thompsonMike kellyHuitt traceyAmerican spinal injury associationNervgen pharma corpCorporate communicationsCompany annual information formShort form base shelf prospectusRegulation services providerBritish columbia newsfile corpVenture exchangeGen pharma

NervGen Pharma Corp : NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting

Phase 1b/2a trial expected to commence in Q3 2023First readout anticipated in 2024Vancouver, British Columbia (Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"

British columbiaUnited kingdomUnited statesNancy thompsonShirley ryan abilitylabHuitt traceyMike kellyShort form base shelf prospectusCorporate communicationsNervgen pharma corpBritish columbia newsfile corpVenture exchangeCompany annual information formRegulation services providerAmerican spinal injury associationGen pharma

NervGen Pharma Corp : NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical

British columbiaUnited kingdomUnited statesDennis riedlNancy thompsonHuitt traceyBritish columbia newsfile corpNervgen pharma corpShort form base shelf prospectusCompany annual information formCorporate communicationsRegulation services providerVenture exchangeGen pharmaExecutive chairmanDaniel mikol

NervGen Completes Dosing Group With MS Candidate NVG-291 | Multiple Sclerosis News Today

NervGen Completes Dosing Group With MS Candidate NVG-291 | Multiple Sclerosis News Today
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Nervgen pharmaDrug administrationDaniel mikol

MS Therapy Candidate NVG-291 Cleared to Enroll 2nd Volunteer Group

MS Therapy Candidate NVG-291 Cleared to Enroll 2nd Volunteer Group
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Nervgen pharmaPaul brennanDrug administrationSafety review committeeDaniel mikol